CV-6209

CV-6209 is a potent antagonist of platelet activating factor (PAF) . CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats[1].

Product Specifications

CAS Number

[100488-87-7]

UNSPSC

12352005

Target

Platelet-activating Factor Receptor (PAFR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cv-6209.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC[N+]1=CC=CC=C1CN(C(C)=O)C(OCC(OC)COC(NCCCCCCCCCCCCCCCCCC)=O)=O.[Cl-]

Molecular Formula

C34H60ClN3O6

Molecular Weight

642.31

References & Citations

[1]Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242 (1) :263-8.|[2]Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study) . J Investig Allergol Clin Immunol. 2017;27 (3) :161-168.|[3]Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352 (3) :541-51.